Approval · Notice of Compliance 19819 · 2017
STIVARGA: Notice of Compliance 19819
Issued September 18, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19819
- Date
- September 18, 2017
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: for the treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| STIVARGA | Not yet assigned | — |
Medicinal ingredients
- REGORAFENIB 40 MG per TAB